NanoViricides/$NNVC
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About NanoViricides
Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company is engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific antiviral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing. The Company's platform is based on host-mimicry and thereby has uniquely enabled the development of broad-spectrum antiviral drugs that the viruses would be unable to escape, a critical unmet need in antiviral therapeutics.
- Ticker
- $NNVC
- Sector
- Health
- Primary listing
- AMEX
- Employees
- 7
- Headquarters
- Shelton, United States
- Website
- www.nanoviricides.com
NanoViricides Metrics
BasicAdvanced
$35M
-
-$0.41
1.66
-
Price and volume
Market cap
$35M
Beta
1.66
52-week high
$1.93
52-week low
$0.85
Average daily volume
204K
Financial strength
Current ratio
2.656
Quick ratio
2.347
Profitability
EBITDA (TTM)
-7.781
Management effectiveness
Return on assets (TTM)
-55.53%
Return on equity (TTM)
-101.46%
Valuation
Price to book
3.66
Price to tangible book (TTM)
3.79
Price to free cash flow (TTM)
-3.581
Free cash flow yield (TTM)
-27.93%
Free cash flow per share (TTM)
-0.385
Growth
Earnings per share change (TTM)
-35.00%
3-year earnings per share growth (CAGR)
-18.01%
10-year earnings per share growth (CAGR)
-20.02%
What the Analysts think about NanoViricides
Analyst ratings (Buy, Hold, Sell) for NanoViricides stock.
Analyst projections of the future price of NanoViricides stock.
NanoViricides Financial Performance
Revenues and expenses
NanoViricides Earnings Performance
Company profitability
Upcoming events
No upcoming events
NanoViricides News
AllArticlesVideos
NanoViricides' Revolutionary Broad-Spectrum Drug Candidate NV-387 Has Successfully Demonstrated Excellent Indications for Safety and Toxicology in a Juvenile Mouse Pups Animal Study, Paving the Way for Pediatric Use in Clinical Trials
Accesswire3 weeks ago
Phase II Clinical Trial of NV-387 Oral Gummies as Treatment of Ebola Progressing Well, Says NanoViricides
Accesswire1 month ago
NanoViricides Presenting at NIBA's 153rd Investment Conference in Fort Lauderdale, FL October 7, 2026
Accesswire1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.